**Highlights of This Issue** vii

**SPECIAL FEATURES**

1085  Finding the Right Dose for Cancer Therapeutics—Can We Do Better?  
Eric H. Rubin and Keaven M. Anderson  
See article p. 1289

1088  Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer  
Amina Zoubeidi, Kim Chi, and Martin Gleave

1094  Targeting the RB-pathway in Cancer Therapy  
Erik S. Knudsen and Jean Y.J. Wang

**CANCER THERAPY: PRECLINICAL**

1129  Comprehensive MicroRNA Profiling for Head and Neck Squamous Cell Carcinomas  
Angela Y.Y. Hui, Michelle Lenarduzzi, Tiffaney Krushel, Levi Waldron, Melania Pintilie, Wei Shi, Bayardo Perez-Ordonez, Igor Jurisica, Brian O’Sullivan, John Waldron, Pat Gullane, Bernard Cummings, and Fei-Fei Liu

1140  X-Linked Ectodermal Dysplasia Receptor Is Downregulated in Breast Cancer via Promoter Methylation  
Vasu Punji, Hittal M, and Preet M. Chaudhary

**Molecular Pathways**

1100  A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations  
Eleni Efthathiou and Christopher J. Logothetis

1108  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma  

1119  Frequent Downregulation of miR-34 Family in Human Ovarian Cancers  

1149  Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias  

1159  AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer  

1170  Blockade of the Extracellular Signal-Regulated Kinase Pathway Enhances the Therapeutic Efficacy of Microtubule-Destabilizing Agents in Human Tumor Xenograft Models  
Kazushi Watanabe, Susumu Tanimura, Aya Uchiyama, Toshiaki Sakamoto, Takumi Kawabata, Kei-ichi Ozaki, and Michiaki Kohno
1179 Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors
Said Akli, Tuyen Bui, Hannah Wingate, Anna Biernacka, Stacy Moulder, Susan L. Tucker, Kelly K. Hunt, and Khandan Keyomarsi

1191 Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

1206 MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

1216 Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography
Nathalie Lassau, Serge Koscielny, Laurence Albiges, Linda Chami, Baya Benatsou, Mohamed Chebil, Alain Roche, and Bernard J. Escudier

1226 Tobacco Use in Human Papillomavirus–Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence

1236 A 3′-Untranslated Region Polymorphism in IGF1 Predicts Survival of Non–Small Cell Lung Cancer in a Chinese Population
Mingfeng Zhang, Zhibin Hu, Jinlin Huang, Yongqian Shu, Juncheng Dai, Guanglu Jin, Rong Tang, Jing Dong, Yijiang Chen, Lin Xu, Xinen Huang, and Hongbing Shen

1245 Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients
Peter Hammarsten, Amar Karalija, Andreas Josefsson, Stina Häggström Rudolfsson, Pernilla Wikström, Lars Egevad, Torvald Granfors, Pär Stattin, and Anders Bergh

1256 A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge, Roy S. Herbst, Michael S. Gordon, S. Gail Eckhardt, Razelle Kurzrock, Blythe Durbin, Josephine Ing, Tanyifor M. Tohnya, Jason Sager, Avi Ashkenazi, Gordon Bray, and David Mendelson

1264 Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis
Florence Dalenc, Sophie F. Doisneau-Sixou, Ben C. Allal, Sabrina Marsili, Valérie Lauwers-Cances, Karima Chaoui, Odile Schiltz, Bernard Monsarrat, Thomas Filleron, Nicole Renée, Emilie Malissein, Elise Meunier, Gilles Favre, and Henri Roché

1272 The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer
Leona Downey, Robert B. Livingston, Maria Koehler, Michael Arbushites, Lisa Williams, Angela Santiago, Roberta Guzman, Ivonne Villalobos, Angelo Di Leo, and Michael F. Press

Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
Rajul K. Jain, J. Jack Lee, David Hong, Maurie Markman, Jing Gong, Aung Naing, Jennifer Wheler, and Razelze Kurzrock
See commentary p. 1085

Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyrididine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer
Charles A. Kunos, Steven Waggoner, Vivian von Gruenigen, Elisa Eldermire, John Pink, Afshin Dowlati, and Timothy J. Kinsella

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
Dae Ho Lee, Keunchil Park, Joo Hang Kim, Jong-Seok Lee, Sang Won Shin, Jin-Hyoung Kang, Myung-Ju Ahn, Jin Seok Ahn, Cheolwon Suh, and Sang-We Kim

Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041)

Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non–Small Cell Lung Cancer
Shuhang Wang, Tongtong An, Jie Wang, Jun Zhao, Zhijie Wang, Minglei Zhuo, Hua Bai, Lu Yang, Yan Zhang, Xin Wang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, and Meina Wu

SUSCEPTIBILITY AND PREVENTION

Smoking and Colorectal Cancer in Lynch Syndrome: Results from the Colon Cancer Family Registry and The University of Texas M.D. Anderson Cancer Center
Mala Pande, Patrick M. Lynch, John L. Hopper, Mark A. Jenkins, Steve Gallinger, Robert W. Haile, Loic LeMarchand, Noralane M. Lindor, Peter T. Campbell, Polly A. Newcomb, John D. Potter, John A. Baron, Marsha L. Frazier, and Christopher I. Amos

LETTERS TO THE EDITOR

Studies of TMPRSS2-ERG Gene Fusions in Diagnostic Trans-Rectal Prostate Biopsies
Gerhardt Attard, Johann S. de Bono, Jeremy Clark, and Colin S. Cooper

Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?
Peter A. Kavsak, Hal Hirte, and Sebastien J. Hotte

CORRECTIONS

Correction: A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors

Correction: The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y] Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin’s Lymphoma: Preclinical Findings and Results of a Phase I Trial
ABOUT THE COVER

Expression of the miR-34 family was found to be frequently reduced in human epithelial ovarian cancer, particularly so in tumors with p53 mutations. The figure shows miR-34a expression (dark blue) in ovarian serous adenocarcinoma as determined by in situ hybridization with locked nucleic acid–modified probes. Immunohistochemistry in serial sections revealed significant inverse correlation between miR-34a and its target MET, an oncogene commonly overexpressed in advanced stages of cancer. For details, see the article by Corney and colleagues on page 1119 of this issue.